Acquisitions21 Apr 2026, 01:12 pm
iSERA Lifesciences to acquire up to 100% of iSERA Biological
AI Summary
The Board of Directors of iSERA Lifesciences Limited (formerly Covidh Technologies Ltd) approved the acquisition of up to 100% of iSERA Biological Limited. Additionally, the Board approved increasing the authorized share capital from ₹11 Crore to ₹25 Crore, adopting new Memorandum and Articles of Association to comply with the Companies Act, 2013, and enhancing the limit for investments, loans, or guarantees under Section 186 of the Companies Act, 2013, to ₹1,000 Crore. The Board also took on record and approved valuation reports and the swap ratio for a proposed preferential issue of equity shares.
Key Highlights
- Board approved acquisition of up to 100% equity in iSERA Biological Limited.
- Authorized share capital increased from ₹11 Cr to ₹25 Cr.
- New MOA/AOA adopted to align with Companies Act, 2013.
- Investment limits under Section 186 enhanced to ₹1,000 Cr.
- Valuation reports and swap ratio for preferential issue approved.